JPS609454A - Food containing component of panax ginseng - Google Patents

Food containing component of panax ginseng

Info

Publication number
JPS609454A
JPS609454A JP58116638A JP11663883A JPS609454A JP S609454 A JPS609454 A JP S609454A JP 58116638 A JP58116638 A JP 58116638A JP 11663883 A JP11663883 A JP 11663883A JP S609454 A JPS609454 A JP S609454A
Authority
JP
Japan
Prior art keywords
saponin
ginseng
component
food
jiaogulan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP58116638A
Other languages
Japanese (ja)
Inventor
Shigeru Yuchi
有地 滋
Yoshihiro Uchida
義弘 内田
Akio Fujikawa
藤川 明男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Chemical Laboratory Co Ltd
Original Assignee
Osaka Chemical Laboratory Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Chemical Laboratory Co Ltd filed Critical Osaka Chemical Laboratory Co Ltd
Priority to JP58116638A priority Critical patent/JPS609454A/en
Publication of JPS609454A publication Critical patent/JPS609454A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

PURPOSE:To provide the titled food containing a gourd saponin substance and a hydrangea saponin substance, and having the same function as Panax ginseng. CONSTITUTION:The whole grass, fruit, seed, bine, sap, etc. of a gourd of the species DARUMA, NAGAITOURI, TOKADOHECHIMA, etc. is extracted with methanol to obtain the gourd saponin substance (A) of formula I . Separately, the hydrangea saponin substance (B) of formula II is prepared by extracting the dried powder of hydrangea with water or hydrated lower alcohol. The component A and the component B are mixed and formed to an arbitrary form of food, e.g. powder, granule, side dish, etc. The amount of the active components to be taken daily by an adult is 20-500mg. The tonic, vitalizing and life-prolonging activities of Panax ginseng can be obtained by taking the above food, and the side-effects of adrenocorticotropic hormone can be prevented.

Description

【発明の詳細な説明】 この発明はチョウセンニンジン成分を含む食品Gこ係り
、その目的はヘチマ抽出サポニン物質とアマチャヅル抽
出サポニン物質との両者を少なくとも含有させてチョウ
センニンジン成分類似の成分とし、この両成分を含ませ
たチョウセンニンジン成分と同様の機能を持つチョウセ
ンニンジン成分を含む食品の提供【こある。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a food product G containing ginseng ingredients, and its purpose is to contain at least both loofah extract saponin substances and Jiaogulan extract saponin substances to produce a food product similar to ginseng ingredients; To provide a food containing a ginseng ingredient that has the same function as the ginseng ingredient containing the ingredient.

チョウセンニンジンは中国東北地方、朝鮮半島。Ginseng is native to the northeastern region of China and the Korean Peninsula.

極東シベリア原産のウコギ科(Ara I i aee
ae )植物。
Araliaceae (Ara I aee) native to Far Eastern Siberia
ae) Plants.

(所謂オタネニンジン)の根のことを言い、一般には強
荘1強精、不良長寿などのような薬効をもった植物であ
ると考えられている。
It refers to the root of the so-called Panax ginseng, and is generally thought to be a plant with medicinal properties such as Qiangzhuang 1 Qiangzei and Longevity.

しかしながら、近年、チョウセンニンジンに関する研究
が進み、主としてチョウセンニンジンに含有されるニン
ジンサポニンがチョウセンニンジンの有効な成分である
という研究が進んでいる。
However, in recent years, research on Panax ginseng has progressed, and research has mainly progressed that ginseng saponin contained in Panax ginseng is an effective component of Panax ginseng.

このようなチョウセンニンジンサポニンは疲労感2食欲
不振2手足の冷え、虚弱体質、血色不良。
These ginseng saponins cause fatigue, loss of appetite, cold hands and feet, weak constitution, and poor complexion.

腰痛、肩こり2頭痛、(i@4. 胃痛、腹部膨h)1
1感、めまい、立ちくらみ等の愁訴症状を主とする各種
疾患に対し有効であるという症状が判明している。
Lower back pain, stiff shoulders 2 Headache, (i@4. Stomach pain, abdominal swelling h) 1
It has been found that it is effective against various diseases, mainly complaints such as feeling dizzy, dizziness, and lightheadedness on standing up.

また、他の症例によっては肝臓機能の増大や肝剛胞の臓
殖促進作用、更Oこは潰瘍に対して有効であるし、特G
こ近年副作用防止剤(特に副腎皮質ホルモンによる)と
いうなどの多くの有要な効果が確認報告されている。
In addition, depending on other cases, it is effective for increasing liver function, promoting the growth of liver cysts, and treating ulcers.
In recent years, many important effects have been confirmed and reported, including as a side effect prevention agent (particularly due to adrenal cortical hormone).

ところが、このチョウセンニンジンはその栽培や原産地
が特定であるということ、更ζこは栽培方法が困難であ
るという問題を持ち、非常Qこ高価なものであってその
同一作用をもたらすものでかっ安価なものが通常経口的
Qこ摂食できる形態であって特に薬効が著るしいが副作
用の大きい副腎皮質ホルモンと併用してその薬害を除去
できるものが必要であるという強い要望があった。
However, this ginseng has the problem that its cultivation and place of origin are specific, and the cultivation method for ginseng is difficult, and it is very expensive, whereas it is much cheaper to produce the same effect. There has been a strong demand for a drug that can be taken orally and that can be used in conjunction with adrenocortical hormones, which have remarkable medicinal efficacy but have large side effects, to eliminate the drug damage.

一方、この発明者らは永年0こ亘り、サポニンノ研究を
続けずでζこアマチャゾル(Gyhos t eron
apentaphyl lum 1x4akino )
がらサポニン物質を抽出単離することOこ成功し、更に
またヘチマ(Luffacyl 1ndrica)から
もヘチマサボニン物質を抽出単離するのに成功した。
On the other hand, these inventors did not continue their research on saponin for many years.
apentaphyl lum 1x4akino)
We succeeded in extracting and isolating a saponin substance from Luffacyl lindrica, and we also succeeded in extracting and isolating a loofah saponin substance from Luffacyl lndrica.

この発明者らはこのようQこサポニンの研究を永年に亘
り続けた結果、驚くべきこと(ここのへチマサポニンこ
とアマチャヅルサポニン内に特にチョウセンニンジンサ
ポニンと同一のサポニンが各々含まれており、・この両
者のサポニンを混合することによってチョウセンニンジ
ン成分と同一のサポニンとなることを解明しこの発明に
至ったものである。
As a result of these long years of research into Q-saponin, the inventors discovered something surprising: the loofah saponin, or Jiaogulan saponin, contains the same saponin as ginseng saponin. This invention was achieved by discovering that by mixing both saponins, the same saponin as the ginseng component can be obtained.

すなわち、この発明はチョウセンニンジン成分を含む食
品に関わるものであり、特にヘチマ(Luffa cy
lihdrica)がら抽出m離された下記に示す一般
式(I)で表わされるヘチマサボニン物質と、アマチャ
ヅルCGynost6]11na Pentaph37
11umMakino)から抽出屯離された下記に示す
一般式(II)で表わされるアマチャヅルサポニン物質
とを少なくとも含有することからなるチョウセンニンジ
ン成分を含む食品に係わるものである。
That is, the present invention relates to foods containing ginseng ingredients, and in particular, to foods containing ginseng ingredients, particularly loofah (Luffa cylindrical).
A loofah sabonin substance represented by the general formula (I) shown below extracted from Gynostemma lihdrica and separated from Jiaogulan CGynost6]11na Pentaph37
The present invention relates to a food containing a ginseng component, which contains at least a Jiaogulan saponin substance represented by the following general formula (II) extracted and separated from 11um Makino.

Rう (R,はO−グルコース、R2は一〇−グルコースス) この発明でヘチマサポニン物質とはヘチマ(Luffa
 cylindrica)がら抽出?41 litされ
た下記0こ示す一1投式(1)で表わされるヘチマサポ
ニン物質である。
R (R, is O-glucose, R2 is 10-glucose) In this invention, the loofah saponin substance is Luffa (Luffa).
cylindrica) extracted? This is a loofah saponin substance expressed by formula (1) shown below.

(R,は0−グルコース R、は−0−グルコース又は
この発明で使用するヘチマとは従来公知のヘチマ例えば
、だるま種、ナガイトゥリ種、トヵドヘチマ種等全てこ
の発明で好適(3使用できるヘチマ(Luffa cy
lindrica)の部位としては藺草、果実。
(R, is 0-glucose R, is -0-glucose or the loofah used in this invention is a loofah that is conventionally known, such as Daruma species, Nagaituri species, Tokado loofah species, etc.) All suitable for this invention (3 Loofahs that can be used (Luffa) cy
Parts of lindrica include rush grass and fruit.

若い果実2種子、つる、−ヘチマ水の全てであり特9こ
果実(種子も含む)かへチマサポニン物質の含有量が多
いので最も望ましい。
Young fruits, seeds, vines, and loofah water are all present, and are especially desirable because they contain a high content of loofah saponin substances.

このようなヘチマ原料を使用してヘチマサポニン物質を
抽出するには、その−製造例を示すと、要すればノルマ
ルヘキサンなどの常法の脱脂溶剤で原料ヘチマ粉末(ヘ
チマ水を除く)を脱脂した後メタノールで加熱抽出し次
いでこの抽出液を減圧蒸留して溶剤を留去する。
In order to extract loofah saponin substances using such loofah raw materials, to give an example of its production, if necessary, the raw loofah powder (excluding loofah water) is defatted using a conventional degreasing solvent such as n-hexane. After that, the mixture is heated and extracted with methanol, and then the extract is distilled under reduced pressure to remove the solvent.

この溶剤留去後の残留物を水飽和n−ブタノール中に攪
拌しながら溶解させ、この溶液を水で洗浄し分離した水
飽和n−ブタノール層を減圧蒸留乾固する。
The residue after distilling off the solvent is dissolved in water-saturated n-butanol with stirring, this solution is washed with water, and the separated water-saturated n-butanol layer is distilled to dryness under reduced pressure.

更に、この乾固物をメタノールGこ溶解させ、この溶液
をエーテル中に注入し所要時間静置した後析出物な炉別
し、この濾過物を減圧乾燥させればヘチマサボニン物質
が得られる。この抽出方法に限定されるものではなく、
例えば減圧乾燥法の代わりQこカラムクロマト吸着精製
法を採用する抽出法であってもよい。
Further, this dried product is dissolved in methanol G, this solution is poured into ether, and after standing for a required period of time, the precipitate is separated in a furnace, and the filtrate is dried under reduced pressure to obtain a loofah sabonin substance. It is not limited to this extraction method,
For example, an extraction method that employs Q column chromatography adsorption purification method instead of vacuum drying method may be used.

このような組へチマサボニン物質を更にシリカゲルカラ
ムクロマトで精製分別すれば下記式(I)で表わされる
ヘチマサボニン物質が得られる。
If such a set of hechima sabonin substances is further purified and fractionated using silica gel column chromatography, a hechima sabonin substance represented by the following formula (I) can be obtained.

(R,は0−グルコース、R2は−O−グルコースまた
、この発明で使用するアマチャヅルサポニンを得るには
アマチャヅル(GynO8ter11Inapenta
phyllum Makino)の全部位地上部また番
よ地下部、あるいは種子をまず乾燥粉末化して調製する
(R, is 0-glucose, R2 is -O-glucose. Also, to obtain Jiaogulan saponin used in this invention, GynO8ter11Inapenta
The entire above-ground part, underground part, or seeds of Phyllum Makino are first prepared by drying and powdering them.

このようなアマチャヅルの乾燥粉末からアマチャヅルサ
ポニンを抽出するにはアマチャヅルを水または倉永低級
アルコールで抽出する。
To extract Jiaogulan saponin from such dry powder of Jiaogulan, Jiaogulan is extracted with water or Kuranaga lower alcohol.

ココで、含水低級アルコールとしては50容慴パ一セン
ト程度以下の含水メタノール、含水エタール等が例示さ
れる。
Examples of water-containing lower alcohols include water-containing methanol and water-containing ethal of approximately 50% or less per volume.

この抽出は、加熱下で行うのが望ましく・。尚、原料の
アマチャヅルは抽出に先だって予め細切りし、あるいは
常法をこより脱脂したものを用(・てもよい。
It is preferable to perform this extraction under heat. Incidentally, the Jiaogulan used as a raw material may be finely chopped or defatted using a conventional method prior to extraction.

また、抽出溶媒として含水低級アルコールを用いた場合
には抽出液を濃縮してアルコール去した後適量の水を加
えて次の非イオン性吸着樹脂での処理Gこ付すのが好ま
しい。
Furthermore, when a water-containing lower alcohol is used as the extraction solvent, it is preferable to concentrate the extract to remove the alcohol, then add an appropriate amount of water and apply the next treatment with a nonionic adsorption resin.

非イオン性吸着樹脂としてはスチレン−ジビニルベンゼ
ン共重合体から成る]1イポ−ラヌなものが望ましい。
As the nonionic adsorption resin, one made of styrene-divinylbenzene copolymer is preferably used.

具体的QこはアノパーライトXAI)−2(米国ローム
アントバー社製)、セファテックスLJI20(ファー
マシャファインケミカルズ社製)等が汎用される。
Specifically, Anopalite XAI)-2 (manufactured by Rohm Antovar, USA), Sephatex LJI20 (manufactured by Pharmacia Fine Chemicals, Inc.), etc. are commonly used.

この処理は吸着樹脂を充填したカラム昏こーIー記で得
られた抽出液を通液して行う。
This treatment is carried out by passing the extract obtained in Section I through a column packed with adsorption resin.

この操作Qこよりサポニンが樹脂に吸着される。Through this operation Q, saponin is adsorbed onto the resin.

次いで樹脂に吸着されだサポニンを低級アルコールで溶
出する。溶出溶媒として用いられる低級アルコールとし
てはメタノール、エタノール等が好ましい。
Next, the saponin adsorbed on the resin is eluted with lower alcohol. As the lower alcohol used as the elution solvent, methanol, ethanol, etc. are preferable.

尚、溶出に先だって予めカラムを水ある(・(よ20容
量パ一セント程度の含水低級アルコール洗浄するのが好
ましい。
In addition, before elution, it is preferable to wash the column with water (20% by volume) in advance with a water-containing lower alcohol.

このようにして得られた低級アルコール溶出液を次いで
アルミナで処理する。
The lower alcohol eluate thus obtained is then treated with alumina.

この処理もアルミナを充填したカラムを用(・て行えば
簡便である。
This process is also convenient if carried out using a column packed with alumina.

この処理によりサポニンはアルミナに吸着される。This treatment causes saponin to be adsorbed onto alumina.

なお、このアルミナでの処理に先ケつてL記の低級アル
コール溶出液を予め適宜濃縮しておし・てもよい。
Note that, prior to this treatment with alumina, the lower alcohol eluate described in L may be appropriately concentrated in advance.

このアルミナに吸着されたサポニンを次し・で低級アル
コールまたは含水低級アルコールしくは50容耽パ一セ
ント程度の含水低級アルコールで、溶出する。
The saponin adsorbed on the alumina is then eluted with a lower alcohol or a water-containing lower alcohol, or with about 50 volumes of a water-containing lower alcohol.

この溶出液を濃縮することGこよりアマチャ゛ノ゛ルサ
ボニンが得られる。
Amature sabonin is obtained by concentrating this eluate.

このようにして得られた粗アマチャヅルす7jミニンは
、更にこのアマチャヅルサポニンを水に溶解し、この水
溶液をスチレン系樹脂例えばサーバクロム5arb−2
(サーバ社製)で処理し非吸着物質を45〜100係メ
タノール水溶液で溶出し抽出液を濃縮後シリカゲルカラ
ムQこ付す。シリカゲルにIQ着されたサポニンを次い
でクロロホルム、低級アルコール、水で好ましくはクロ
ロホルム、メタノール、水(65:35:10下〕Ij
IJ)で溶出すれば良い。
The crude Jiaogulan saponin thus obtained is prepared by dissolving the Jiaogulan saponin in water and adding this aqueous solution to a styrene resin such as Serverchrome 5arb-2.
(manufactured by Server), unadsorbed substances are eluted with a 45-100 methanol aqueous solution, the extract is concentrated, and then applied to a silica gel column Q. The IQ-deposited saponin on silica gel is then mixed with chloroform, lower alcohol, and water, preferably chloroform, methanol, and water (65:35:10).
It is sufficient to elute with IJ).

(以下の構造式(n)の物質を含むアマチャヅルサポニ
ンが得られる。) ルコーヌ) このようにして得られたアマチャヅルサポニンは前記式
(旧で表わされるサポニンを含むものである。
(A Jiaogulan saponin containing a substance represented by the following structural formula (n) is obtained.) Lecone) The Jiaogulan saponin thus obtained contains a saponin represented by the above formula (old formula).

この発明で使用するヘチマサポニン前記式(1)で示さ
れるサポニンはニンジンサポニン中ReとRg工とζこ
該当し、一方アマチャヅルザボニンはRg2とR111
に該当する。
The saponin represented by the formula (1) used in this invention corresponds to Re and Rg in carrot saponin, while Jiaogulan saponin corresponds to Rg2 and R111.
Applies to.

この発明においては、式(I)で表わされるヘチマサポ
ニンと式(II)で表わされるアマチャヅルサポニンと
を、成人で2omg乃至500 mg/ I−1摂食で
き得る様な食品形態(散剤、果粒、清涼飲料水。
In this invention, loofah saponin represented by formula (I) and Jiaogulan saponin represented by formula (II) are prepared in a food form (powder, granules) that can be ingested by an adult at 2 omg to 500 mg/I-1. , soft drinks.

主食、副食、菓子)等の任意形態とすればよい。It may be in any form such as a staple food, a side dish, or a confectionery.

この発明に係るチョウセンニンジン成分を含有する食品
は摂食老に対し、強壮1強精、不老長寿等のチョウセン
ニンジン類似の効果を有することに加え、副腎皮質ホル
モンの副作用を防止する効果も有する画期的食品である
The food containing the ginseng component according to the present invention not only has effects similar to ginseng, such as tonicity, vitality, and longevity, but also has the effect of preventing the side effects of adrenocortical hormones. It is a seasonal food.

このようにして製造されたアマチャヅルサポニン成分R
g2. Rh、とヘチマサポニンRe及びRg。
Jiaogulan saponin component R produced in this way
g2. Rh, and loofah saponins Re and Rg.

を使用した食品の副腎皮質ホルモンの副作用防止の薬理
試験例と治療例を挙げる。
Examples of pharmacological tests and treatments for preventing the side effects of adrenocortical hormones in foods using .

薬理試験 1、副腎萎縮および血漿コルチゾールに対する影響 A)体重130±2gの雄うット1群lO匹の各群暑こ
、デキサメサゾン5 mg、、/ l gを10目間腹
腔内投与し、11目目から各群1σに(等は混合した)
サポニン成分] 4 mg/kgをそれぞれ10日間腹
腔内投与した。対照として生理食塩水とニンジンサポニ
ン(チョウセンニンジン)14mgとを] me/kg
腹腔内投与を11目目からIO日日間けた。
Pharmacological Test 1, Effects on Adrenal Atrophy and Plasma Cortisol A) 1 group of 10 male rats weighing 130 ± 2 g each group received 5 mg/l g of dexamethasone intraperitoneally for 10 days, and From eye to eye, each group is 1σ (etc. are mixed)
Saponin component] 4 mg/kg of each was administered intraperitoneally for 10 days. Physiological saline and 14 mg of ginseng saponin (Ginseng ginseng) as a control] me/kg
Intraperitoneal administration was continued for 10 days from the 11th day.

開腹してそれぞれの群の副腎の重量と血漿コルチゾール
計を測定した。
Laparotomy was performed to measure the adrenal gland weight and plasma cortisol level of each group.

B) A)と同様に、10匹1群のラットにそれぞれサ
ポニン成分10mg/kg、 ニンジンサポニンI O
mg7kg及び対照として生理食塩水1me/kgを各
群Oこ10[1開運1読投与し、1111目より汁群ラ
ットにデキサメサゾン5 mg、、//cyをloLl
間腹腔内投与した後、開腹して副腎の重置と血漿コルチ
ゾールはを測定した。
B) Same as A), each group of 10 rats was given 10 mg/kg of saponin component and carrot saponin I O
7 kg of physiological saline and 1 me/kg of physiological saline as a control were administered to each group for 1 day, and from day 1111, dexamethasone 5 mg, //cy was administered to the rats in the soup group.
After intraperitoneal administration, laparotomy was performed to measure the position of the adrenal glands and plasma cortisol.

上記A)、 B)から分るようにサポニン成分は、副腎
萎に+による重用の減少、並びに血漿コルチゾールの減
少O二対してニンジンサポニンと同様の顕著な効果を■
する。 またその効果は事1’liJ投与であるB)の
場合をこし認ill’)られ、サポニン成分及びその構
成成分が防止のみならず予防にも有効であることが分る
As can be seen from A) and B) above, the saponin component has the same remarkable effect as carrot saponin on reducing adrenal atrophy and decreasing plasma cortisol.
do. The effect was also confirmed in the case of B), which is 1'liJ administration, and it is clear that the saponin component and its constituent components are effective not only for prevention but also for prevention.

臨床治験例 症例1゜ 59才女性、5年前をこ慢性腎炎と診断され、2年前よ
りプレドニゾロンを服用、服用4ケ月目にバッファロー
ネックが出現した。 プレドニゾロン5mgとサポニン
成分+oomgを含有する散剤を朝、夕2回毎l」服用
した。 バッフアロ−イ・ツタはこの散剤の服用後次第
に消失し、3ケ月後Qこは頚部と肩に部が区別できるよ
う昏こなった。 更に3ケ月服用を続け、浮腫、倦怠 
′感等が消失した。
Clinical Trial Example Case 1: A 59-year-old female was diagnosed with chronic nephritis 5 years ago and began taking prednisolone for 2 years. Buffalo neck developed after 4 months of taking the drug. A powder containing 5 mg of prednisolone and a saponin component + oomg was taken twice in the morning and evening. After taking this powder, the buffaloise ivy gradually disappeared, and three months later, the patient became comatose with distinguishable areas on his neck and shoulders. After continuing to take the drug for another 3 months, edema and fatigue occurred.
The feeling of '' disappeared.

症例2゜ 63才女性、慢性リウマチ性ヒザ関節炎と診断され、プ
レドニゾロンを毎ト120 mg内服していたところ、
尿q月7−0HC3I mg1日、+7−KS5 mg
/ Bと副腎皮質機能が低下していた。
Case 2: A 63-year-old woman was diagnosed with chronic rheumatoid knee arthritis and was taking 120 mg of prednisolone every day.
Urine q month 7-0HC3I mg 1 day, +7-KS5 mg
/ B and adrenal cortical function was decreased.

プレドニゾロン投与を中11ニし、1g中サすニン成分
5 Q mgを含有する散剤を、1目当り4y(サポニ
ン成分として200 mg )を朝夕2回に分けて1ケ
月間服用した。尿中17−0HC310μg/El、 
I 7−KS I Omg/lコと副腎皮質機能が改善
されると八に、ウイズドローワル症候、リバウンド現象
の出現をみなかった。
Prednisolone was administered for 11 days, and a powder containing 5 Q mg of the saponin component in 1 g was taken for 1 month at 4 y (200 mg as the saponin component) per eye, divided twice in the morning and evening. Urinary 17-0HC310μg/El,
When the adrenal cortex function was improved to 7-KS I Omg/l, no withdrawal symptoms or rebound phenomenon were observed.

症例3゜ 32才男性、慢性リウマチ性関節炎で副腎皮質ホルモン
の服用はなかった。 プレトニゾ「」ン5 mgとサポ
ニン成分10mgを含有する散剤を朝夕2回毎11服用
した。 服用4ケ月1麦、ステロイドの副作用が出現す
ることなくヒザ関節の疼痛、浮腫、運動障害が消失した
Case 3: A 32-year-old male with chronic rheumatoid arthritis who did not take adrenocortical hormones. A powder containing 5 mg of pretonisone and 10 mg of saponin was taken twice in the morning and evening for 11 days. After taking 1 barley for 4 months, the pain, edema, and movement disorder in the knee joint disappeared without any steroid side effects.

症例4゜ 50才女性、左手11月こ熱湯がかかり、20crlの
水泡を形成し、4c4程破れ、びらん面を呈して分泌液
が滲出していた。 サポニン成分50Tngとプレドニ
ゾロン5mg含有錠剤をI l’l 21ij口錠づつ
内服、患部Gこサポニン成分(1%”/)■ とプレドニゾロン(0,5% W/v) 倉有軟・陣を
塗布。 2日後分泌液が消失して結向乾燥した。
Case 4: A 50-year-old woman was exposed to boiling water on her left hand in November, resulting in a 20crl blister, which had ruptured to the extent of 4c4 and had an erosive surface with secretions oozing out. Tablets containing 50 Tng of saponin component and 5 mg of prednisolone were taken orally, and saponin component (1%''/)■ and prednisolone (0.5% W/v) were applied to the affected area. After 2 days, the secreted fluid disappeared and it was dried.

5日後に治癒したが色素異常、偏−轍も出現しなかった
。 その間ステロイドの副作用もなく、従来のステロイ
ド単独投与の治験例からみて驚くべき早期効果がみられ
た。
It healed after 5 days, but no pigment abnormality or uneven ruts appeared. During this time, there were no side effects of steroids, and surprising early effects were seen compared to conventional clinical trials of steroid administration alone.

−9・-9・

Claims (1)

【特許請求の範囲】[Claims] (1)ヘチ−v (Luffa cylindrica
)から抽出jli 肖1tされた下記に示す一般式(1
)で表わされるヘチマサポニン物質と、アマチャヅル(
Gynos t errmapentaphyllum
 Makino)から抽出単離された下記昏こ示す一般
式(n)で表わされるアマチャヅルサポニン物質を少な
くとも含有することからなるチョウセンニンジン成分を
含む食品。 又はO−グルコース−ラムノースを示すn)(R1はO
−グルコース−ラムノース又はO−グルコース)
(1) Luffa cylindrica
) is extracted from the following general formula (1
) and the luffa saponin substance expressed by Jiaogulan (
Gynost errmapentaphyllum
1. A food containing a ginseng component, which contains at least a Jiaogulan saponin substance represented by the general formula (n) shown below, extracted and isolated from Makino. or O-glucose-rhamnose) (R1 is O
-glucose-rhamnose or O-glucose)
JP58116638A 1983-06-27 1983-06-27 Food containing component of panax ginseng Pending JPS609454A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58116638A JPS609454A (en) 1983-06-27 1983-06-27 Food containing component of panax ginseng

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58116638A JPS609454A (en) 1983-06-27 1983-06-27 Food containing component of panax ginseng

Publications (1)

Publication Number Publication Date
JPS609454A true JPS609454A (en) 1985-01-18

Family

ID=14692153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58116638A Pending JPS609454A (en) 1983-06-27 1983-06-27 Food containing component of panax ginseng

Country Status (1)

Country Link
JP (1) JPS609454A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6415053A (en) * 1987-07-09 1989-01-19 Shirakawa Seisakusho Kk Method for sterilizing, deodorizing, discoloring and drying feather material by ozonized air
CN105685991A (en) * 2016-03-24 2016-06-22 福建春辉生物工程有限公司 Camellia seed crude oil composition capable of treating stomach diseases and preparation method of camellia seed crude oil composition
US9670119B2 (en) 2010-07-09 2017-06-06 Celanese International Corporation Process for producing ethanol using multiple beds each having different catalysts

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6415053A (en) * 1987-07-09 1989-01-19 Shirakawa Seisakusho Kk Method for sterilizing, deodorizing, discoloring and drying feather material by ozonized air
JPH0371902B2 (en) * 1987-07-09 1991-11-14 Shirakawa Seisakusho Kk
US9670119B2 (en) 2010-07-09 2017-06-06 Celanese International Corporation Process for producing ethanol using multiple beds each having different catalysts
CN105685991A (en) * 2016-03-24 2016-06-22 福建春辉生物工程有限公司 Camellia seed crude oil composition capable of treating stomach diseases and preparation method of camellia seed crude oil composition

Similar Documents

Publication Publication Date Title
KR100877604B1 (en) Composition comprising an extract of processed ginseng for preventing and treating obesity
WO2006060951A1 (en) A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof
JP2012021022A (en) Medicinal preparation containing phenylethanoid glycoside extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process for producing the same and use thereof
JPS6352013B2 (en)
CN110893197B (en) Panax notoginseng extract for treating gout and preparation method thereof
Chawla et al. A review of chemistry and biological activities of the genus Aerva--a desert plant
CN1833692B (en) False portulaca oleracea extracts, its prepn. and usage
CN104997878A (en) Auxiliary blood pressure and blood fat reducing health product and preparation process thereof
KR20100117074A (en) Composition containing capsicum for treating a skin disorder
CN106967147A (en) C27Spirostan type steroid saponin compounds and its pharmaceutical composition and its application
US20100021568A1 (en) Anti-Obesity Product And Its Method Of Preparation
CN1331484C (en) Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation
KR100302063B1 (en) Complement activity controlling agent containing ginseng saponin and sapogenin
US6280737B1 (en) Harpagoside-enriched extract from harpagophytum procumbens and processes for producing same
JP4693964B2 (en) New antifeedant
JPS609454A (en) Food containing component of panax ginseng
CN117064965A (en) Prostate golden erysipelas tablet and preparation method thereof
WO2006050642A1 (en) A composition containing panaxadial saponins and its preparation and application
CN106074588A (en) The combination of Rhizoma Paridis forrestii monomer saponin and pharmaceutical composition and its application in pharmacy
KR20130074121A (en) Ginseng prosapogenin high concentration containing sanchi ginseng preparation using sonication and process for thereof
JPS6037960A (en) Health drink
CN103961615B (en) A kind of Chinese medicine composition treating rhagadia manus et pedis and preparation thereof
CN109481531B (en) Qi-benefiting and blood-nourishing composition as well as preparation method and application thereof
CN102961418B (en) Compound Hippophae rhamnoides dipyridamole tablet and preparation method thereof
CN106309528B (en) Radix cynanchi wilfordii extract, preparation method thereof and application thereof in reducing blood sugar